Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced on 2/8/19 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational drug CP101 for the treatment of patients with recurrent Clostridium difficile (C. difficile) infection.